Thierry J. Alcindor

Montreal, QC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 70 publications

Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair Deficiency.

Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair Deficiency.

Journal: JCO precision oncology

Published: July 06, 2026

Reply to: In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

Reply to: In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 24, 2026

Clinicopathologic Study of 39 Mismatch Repair-deficient Sarcomas Demonstrates Recurrent Histologic Patterns and Supports Universal Screening of Pleomorphic Rhabdomyosarcoma, Uterine Leiomyosarcoma, and Undifferentiated and Unclassified Sarcomas.

Clinicopathologic Study of 39 Mismatch Repair-deficient Sarcomas Demonstrates Recurrent Histologic Patterns and Supports Universal Screening of Pleomorphic Rhabdomyosarcoma, Uterine Leiomyosarcoma, and Undifferentiated and Unclassified Sarcomas.

Journal: The American journal of surgical pathology

Published: March 21, 2026

ESMO podcast on upper gastrointestinal cancers-highlights in esophagogastric cancers from ASCO 2025.

ESMO podcast on upper gastrointestinal cancers-highlights in esophagogastric cancers from ASCO 2025.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.

Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 20, 2025

In search of the best perioperative treatment for gastroesophageal cancer: is there a role for antiangiogenesis?

In search of the best perioperative treatment for gastroesophageal cancer: is there a role for antiangiogenesis?

Journal: Journal of gastrointestinal oncology

Published: September 21, 2025

INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer.

INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 04, 2024

Phase 2 trial of perioperative chemo-immunotherapy for gastro-esophageal adenocarcinoma: The role of M2 macrophage landscape in predicting response.

Phase 2 trial of perioperative chemo-immunotherapy for gastro-esophageal adenocarcinoma: The role of M2 macrophage landscape in predicting response.

Journal: Cell reports. Medicine

Published: July 18, 2024

Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial.

Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial.

Journal: EClinicalMedicine

Published: June 06, 2024

Building the Evidence for Systemic Treatment in Desmoid Fibromatosis: Is a New Metronomic Regimen Another Layer in the Foundation?

Building the Evidence for Systemic Treatment in Desmoid Fibromatosis: Is a New Metronomic Regimen Another Layer in the Foundation?

Journal: JCO global oncology

Published: May 09, 2024

Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma.

Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 04, 2024

Immunotherapy in Gastric Cancer-Choosing Methods or Results.

Immunotherapy in Gastric Cancer-Choosing Methods or Results.

Journal: JAMA oncology

Published: April 04, 2024

Showing 1-12 of 70

Last Updated: 09/26/2026